|
Combination of a therapeutic cancer vaccine and immune checkpoint inhibitors in prostate cancer. |
|
|
Speakers' Bureau - Boehringer Ingelheim (I); Janssen (I); Pfizer (I) |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon |
Research Funding - Ambry Genetics (Inst); Bavarian Nordic (Inst); Johnson & Johnson (Inst); Sotio (Inst) |
|
|
Patents, Royalties, Other Intellectual Property - I am listed as an inventor on an NIH patent. (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Precision Biologics |
Leadership - Precision Biologics |
Stock and Other Ownership Interests - Precision Biologics |
Patents, Royalties, Other Intellectual Property - have patents held by Precision Biologics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bavarian Nordic (Inst) |
Patents, Royalties, Other Intellectual Property - If applicable; If applicable (Inst) |
|
|
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); EMD Serono (Inst); NantBioScience (Inst); Pfizer (Inst) |